Group 1 - The company Hasi Lian (SZ 002900) held its 23rd meeting of the fourth board of directors on August 25, 2025, via telecommunication voting, discussing the proposal for the 2025 semi-annual report [1] - For the year 2024, Hasi Lian's revenue composition is as follows: pharmaceutical industry 87.34%, veterinary medicine 6.64%, other businesses 5.44%, cosmetics 0.45%, and functional foods 0.12% [1] - As of the report date, Hasi Lian's market capitalization is 4.7 billion yuan [1] Group 2 - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related companies [1]

格隆汇8月26日丨哈三联(002900.SZ)公布2025年半年度报告，上半年公司实现营业收入4.13亿元，同比 下降21.08%；归属于上市公司股东的净利润-9239.04万元，同比盈转亏；归属于上市公司股东的扣除非 经常性损益的净利润-8919.59万元；基本每股收益-0.29元。 ...

哈三联(002900.SZ)发布2025年半年度报告，报告期内，公司实现营业收入4.13亿元，同比下降21.08%。 归属于上市公司股东净亏损9239.04万元。归属于上市公司股东的扣除非经常性损益净亏损8919.59万 元。基本每股亏损0.29元。 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-047 哈尔滨三联药业股份有限公司 2025 年半年度募集资金存放与使用情况专项报告 一、募集资金基本情况 经中国证券监督管理委员会许可[2017]1602 号文核准，并经深圳证券交 易所同意，本公司由主承销商安信证券股份有限公司于 2017 年 9 月 12 日 向社会公众公开发行普通股（A 股）股票 5,276.67 万股，每股面值 1 元， 每股发行价人民币 18.07 元。截至 2017 年 9 月 18 日止，本公司共募集资金 953,494,269.00 元 ， 扣 除 发 行 费 用 53,375,312.82 元 ， 募 集 资 金 净 额 900,118,956.18 元。 截至 2017 年 9 月 18 日，本公司上述发行募集的资金已全部到位，业 经大华会计师事务所（特殊普通合伙）以"大华验字[2017]000685 号"验资报 告验证确认。 截至 2025 年 6 月 30 日，公司对募集资金项目累计投入 780,143,509.34 元，其中：公司于募集资金到位之前利用自有资金先期投入募集资金项目 人民币 126,881, ...

证券代码：002900 证券简称：哈三联 公告编号：2025-044 哈尔滨三联药业股份有限公司 第四届监事会第十八次会议决议公告 经审核，监事会认为董事会编制和审议公司 2025 年半年度报告的程序符合 法律、行政法规和中国证监会的相关规定，报告内容真实、准确、完整地反映了 上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决情况：有效表决 3 票，同意 3 票；反对 0 票；弃权 0 票。 一、监事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下简称"公司"）第四届监事会第十八 次会议通知以电子邮件及微信方式于 2025 年 8 月 15 日发出。 2、本次会议于 2025 年 8 月 25 日在公司会议室以现场表决方式召开。 3、本次会议应到监事 3 人，实际出席并表决的监事 3 人。 4、公司监事会主席翟玉平先生主持了会议。 5、本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律、 行政法规、部门规章、规范性文件及《哈尔滨三联药业股份有限公司章程》的有 关规定。 二、监事会会议审议情况 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-043 哈尔滨三联药业股份有限公司 第四届董事会第二十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下或简称"公司"）第四届董事会第二 十三次会议通知以电子邮件及微信方式于 2025 年 8 月 15 日发出。 2、本次会议于 2025 年 8 月 25 日以通讯表决的方式召开。 3、本次会议应到董事 9 名，实际出席并表决的董事 9 名。 4、公司董事长秦剑飞先生主持了会议，公司监事及总裁列席。 5、本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律、 行政法规、部门规章、规范性文件及《哈尔滨三联药业股份有限公司章程》的有 关规定。 二、董事会会议审议情况 会议审议并通过以下议案： 1、审议通过《关于 2025 年半年度报告全文及摘要的议案》 表决情况：有效表决 9 票，同意 9 票，反对 0 票，弃权 0 票。 表决结果：通过。 《2025 年半年度报告全文》请详见同日刊登在公司指定信息披露网站巨潮 资讯网（ ...

Financial Performance - The company's operating revenue for the first half of 2025 was CNY 413.12 million, a decrease of 21.08% compared to CNY 523.44 million in the same period last year[18]. - The net profit attributable to shareholders of the listed company was a loss of CNY 92.39 million, representing a decline of 451.68% from a profit of CNY 26.27 million in the previous year[18]. - The basic and diluted earnings per share were both CNY -0.29, a decrease of 462.50% compared to CNY 0.08 in the same period last year[18]. - The pharmaceutical segment reported sales revenue of 356 million yuan, a decrease of 24.25% year-on-year, accounting for 86.08% of total revenue[34]. - The company reported a significant decline in sales prices due to intensified market competition and national drug procurement policies, resulting in a revenue drop of 110 million yuan year-on-year[49]. - The company achieved operating revenue of 413.12 million yuan, a decrease of 21.08% compared to the same period last year[48]. - The net profit attributable to shareholders was -92.39 million yuan, down 451.68% year-on-year[48]. - The company reported a significant increase in financial expenses by 286.87%, primarily due to reduced interest income and government subsidies[63]. - The company reported a total revenue of 1,123.11 million yuan for the first half of 2025 from its subsidiary Longjiang Dongbao, which is still in the market expansion phase with a negative gross margin of -832.13 million yuan[83]. Cash Flow and Liquidity - The net cash flow from operating activities was CNY 43.89 million, a significant improvement of 169.87% compared to a negative cash flow of CNY 62.81 million in the same period last year[18]. - The cash and cash equivalents decreased by 934.43%, amounting to -¥33,749,092.52, compared to an increase of ¥4,044,569.34 in the previous year[63]. - The company’s cash and cash equivalents decreased, contributing to a tighter liquidity position[168]. - Cash flow from operating activities generated a net amount of ¥43.89 million in the first half of 2025, a significant improvement compared to a net outflow of ¥62.81 million in the first half of 2024[177]. - The total cash inflow from financing activities was $700.58 million, down from $801.64 million year-over-year[180]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3.57 billion, down 6.12% from CNY 3.80 billion at the end of the previous year[18]. - The company's total assets decreased from CNY 3,800,468,270.17 to CNY 3,567,796,395.28, a reduction of approximately 6%[164]. - The company's total current assets decreased from CNY 1,471,966,906.93 to CNY 1,162,127,999.16, a decline of approximately 21%[162]. - Total liabilities decreased from CNY 1,636,313,285.80 to CNY 1,559,323,549.81, a decline of about 5%[164]. - The company's short-term borrowings rose to ¥642.42 million, representing 18.01% of total liabilities, an increase of 2.86% from the previous year[71]. Research and Development - The company is committed to strengthening its research and development capabilities in response to the challenges posed by the evolving pharmaceutical landscape[27]. - The company's R&D investment has consistently accounted for over 8% of its operating revenue, focusing on innovative drug development[57]. - Research and development expenses for the first half of 2025 were CNY 37.94 million, down 21.2% from CNY 48.16 million in the first half of 2024[171]. - The R&D department focused on classic drugs with clear clinical value, successfully obtaining production approvals for several new products, including a breakthrough drug in the nephrology field[39]. Market and Industry Trends - The pharmaceutical industry in China is experiencing a structural adjustment, with a revenue growth rate of 0.8% in the first four months of 2025, significantly lower than the overall industrial growth rate of 6.4%[26]. - The national drug procurement policy is expected to cover around 700 drug varieties by the end of 2025, with the average price reduction exceeding 60% in the latest procurement round[29][30]. - The company is adapting to ongoing policy changes and market dynamics by reducing operational costs and enhancing management efficiency[33]. - The company is actively exploring e-commerce sales and multi-channel development strategies to penetrate the outpatient market[37]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company is actively investing in animal health and wellness sectors while optimizing internal operational efficiency to enhance business quality[33]. - The company is focusing on reducing production costs in the veterinary medicine sector to achieve profitability after experiencing initial losses[83]. - The company is exploring potential mergers and acquisitions to strengthen its market position[82]. Shareholder and Governance Matters - The company has committed to not transferring or entrusting the management of its shares for 12 months post-IPO, with a lock-up period extending for an additional 6 months if certain conditions are met[110]. - The company has established a commitment to comply with regulations regarding share reduction by major shareholders and executives[110]. - The company will comply with the regulations set by the China Securities Regulatory Commission regarding the reduction of shares by shareholders and senior management[111]. - The company emphasizes its commitment to transparency and accountability in its financial disclosures and investor relations[112]. Compliance and Regulatory Issues - The semi-annual financial report was not audited[119]. - The company did not experience any bankruptcy reorganization matters during the reporting period[120]. - There were no significant litigation or arbitration matters during the reporting period[122]. - The company reported no penalties or rectification situations during the reporting period[123]. Future Outlook - The company plans to focus on market expansion and new product development to improve future performance[172]. - The company plans to continue its market expansion strategy, focusing on increasing its equity base and enhancing shareholder value[186]. - The company has a future outlook for continued investment in new product development and market expansion strategies[82].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002900 证券简称：哈三联 公告编号：2025-042 哈尔滨三联药业股份有限公司 备查资料 1、北京哈三联科技有限责任公司营业执照。 特此公告。 变更前： 法定代表人：秦剑飞 变更后： 法定代表人：刘荣 除法定代表人变更外，北京哈三联科技有限责任公司《营业执照》的其他登记事项均保持不变。 关于全资子公司变更法定代表人并完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 哈尔滨三联药业股份有限公司收到全资子公司北京哈三联科技有限责任公司的通知，其对法定代表人进 行了变更，并已完成工商变更登记手续，取得了北京市昌平区市场监督管理局换发的《营业执照》。具 体变更情况如下： 哈尔滨三联药业股份有限公司 董事会 2025年08月15日 ...

Group 1 - The latest stock price of Harsan is 15.08 yuan, an increase of 0.17 yuan compared to the previous trading day [1] - The stock reached a high of 15.18 yuan and a low of 14.70 yuan during the trading session, with a trading volume of 98,600 hands and a transaction amount of 147 million yuan [1] - The company operates in the chemical pharmaceutical industry, with main business activities including pharmaceutical manufacturing, medical devices, and cosmetics [1] Group 2 - The company's wholly-owned subsidiary, Beijing Harsan Technology Co., Ltd., has recently completed a business registration change, with the legal representative changing from Qin Jianfei to Liu Rong [1] - On August 15, the net inflow of main funds was 2.0491 million yuan, while the cumulative net outflow over the past five trading days was 41.2229 million yuan [1]

证券日报网讯8月15日晚间，哈三联（002900）发布公告称，全资子公司北京哈三联科技有限责任公司 完成工商变更登记，法定代表人由秦剑飞变更为刘荣。 ...